Literature DB >> 11903749

Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.

H Okuda1, T Nakanishi, K Takatsu, A Saito, N Hayashi, M Yamamoto, K Takasaki, M Nakano.   

Abstract

BACKGROUND: There has been no comparative study of the clinicopathological features of HCC patients who are seropositive for alpha-fetoprotein (AFP) alone and those who are seropositive for des-gamma-carboxy prothrombin (DCP) alone. The authors, thus, performed this comparative study.
METHODS: The clinicopathological features of patients with solitary hepatocellular carcinoma (HCC), who underwent a hepatectomy were compared among the four below groups according to the seropositivity of AFP and DCP: group A, seronegative for both AFP below 20 ng/mL and DCP below 40 mAU/mL; group B, seropositive for AFP above 100 ng/mL and seronegative for DCP; group C, seronegative for AFP and seropositive for DCP above 100 mAU/mL; and group D, seropositive for both AFP and DCP.
RESULTS: Group B patients showed a higher incidence of HCC with an indistinct margin, and a somewhat higher incidence of small HCC less than 2 cm in greatest dimension compared with group C patients. By contrast, group C patients had a higher frequency of HCC with a distinct margin compared with that of an indistinct margin, large tumors more than 3 cm compared with that of small tumors less than 2 cm, and a somewhat higher frequency of moderately to poorly differentiated HCC compared with that of well-differentiated HCC. Our HCC cases showed advanced clinicopathological features in the order of group C, group B and group A. Groups C and D patients showed similar characteristics.
CONCLUSIONS: Hepatocellular carcinoma patients who were seropositive for AFP alone demonstrated clinicopathological features of less advanced HCC compared with those who were seropositive for DCP alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903749     DOI: 10.1046/j.1440-1746.2001.02610.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  15 in total

1.  Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.

Authors:  Hideaki Kinugasa; Kazuhiro Nouso; Yasuto Takeuchi; Tetsuya Yasunaka; Hideki Onishi; Shin-ichiro Nakamura; Hidenori Shiraha; Kenji Kuwaki; Hiroaki Hagihara; Fusao Ikeda; Yasuhiro Miyake; Akinobu Takaki; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2011-11-03       Impact factor: 7.527

Review 2.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

Review 3.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

4.  Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma.

Authors:  Keun Soo Ahn; Daniel R O'Brien; Yong Hoon Kim; Tae-Seok Kim; Hiroyuki Yamada; Joong-Won Park; Sang-Jae Park; Seoung Hoon Kim; Cheng Zhang; Hu Li; Koo Jeong Kang; Lewis R Roberts
Journal:  Liver Cancer       Date:  2021-09-22       Impact factor: 11.740

5.  An overview of biomarkers for the diagnosis of hepatocellular carcinoma.

Authors:  Mona Abu El Makarem
Journal:  Hepat Mon       Date:  2012-10-20       Impact factor: 0.660

6.  Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Eisuke Ozawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Takashi Goto; Noboru Kinoshita; Masanori Fukushima; Hiroyuki Kato; Kazuyuki Ohata; Kazuo Ohba; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2013-09-06

7.  Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis.

Authors:  Bin Hu; Xiaohui Tian; Jie Sun; Xiangjun Meng
Journal:  Int J Mol Sci       Date:  2013-12-02       Impact factor: 5.923

8.  Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma.

Authors:  Shin Ok Jeong; Eui Bae Kim; Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Sang Gyune Kim; Sang Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; Yong Jae Kim; Dong Erk Goo; Su Yeon Park
Journal:  Gut Liver       Date:  2017-05-15       Impact factor: 4.519

9.  Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.

Authors:  Aline Mähringer-Kunz; Arndt Weinmann; Irene Schmidtmann; Sandra Koch; Sebastian Schotten; Daniel Pinto Dos Santos; Michael Bernhard Pitton; Christoph Dueber; Peter Robert Galle; Roman Kloeckner
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

10.  Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study.

Authors:  Akpakip I Ette; Dennis A Ndububa; Olusegun Adekanle; Udeme Ekrikpo
Journal:  BMC Gastroenterol       Date:  2015-09-04       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.